Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 1201 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Locations: - Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
+ 624 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 253 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Locations: - Alabama Oncology — Birmingham, Alabama
- Clearview Cancer Institute — Huntsville, Alabama
- Palo Verde Hematology Oncology — Glendale, Arizona
+ 181 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Locations: - Research Site — Dothan, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
+ 145 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Locations: - Alaska Oncology and Hematology — Anchorage, Alaska
- Ironwood Cancer & Research Centers — Chandler, Arizona
- Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
+ 114 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
+ 99 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Locations: - Central Alabama Research — Birmingham, Alabama
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
- Western Reg MC-COH Phoenix — Goodyear, Arizona
+ 69 more sites in the U.S.
Phase 3 Recruiting Industry
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced…
Sponsor: AstraZeneca
NCT ID: NCT04862663
Locations: - Research Site — Tucson, Arizona
- Research Site — Fountain Valley, California
- Research Site — Glendale, California
+ 50 more sites in the U.S.
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine…
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06016738
Locations: - Clinical Trial Site — Tucson, Arizona
- Clinical Trial Site — Fountain Valley, California
- Clinical Trial Site — Glendale, California
+ 44 more sites in the U.S.
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Locations: - City of Hope - Cancer Center Phoenix — Goodyear, Arizona
- Tucson Medical Center HealthCare - Tucson-Rudasill — Tucson, Arizona
- City of Hope - Duarte Cancer Center — Duarte, California
+ 42 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Locations: - Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
- Research Site — La Jolla, California
+ 39 more sites in the U.S.